Drug Trial Radar · NCT05519475
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Feb 9, 2023
Primary completion
Apr 27, 2028
Study completion Dec 7, 2028
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Aug 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have Metabolic dysfunction-Associated SteatoHepatitis (MASH). MASH is a form of Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD). MASH occurs when fat builds up in liver cells, damaging them, and making the liver inflamed and stiff from fibrosis (scar tissue). MASH can progress to cirrhosis (long term scarring) and liver failure (when the liver cannot perform its job). The aim of the study is to see the effect of the study drug on lessening liver scarring related to MASH. The study is looking at several other research questions, including: * How ALN-HSD works to improve liver function and lessen MASH-related inflammation in the liver * What side effects may happen from receiving the study drug * How much study drug and study drug metabolites (byproduct of the body breaking down the study drug) are in the blood at different times * Better understanding of the study drug and MASH
Conditions
- Metabolic Dysfunction-Associated SteatoHepatitis (MASH)
Interventions
ALN-HSDDrug
Administered per the protocol
PlaceboDrug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in quantitative liver Fibrosis (qFibrosis)Time frame: Baseline to week 52
Locations
71 sites in 4 countries. Site status is shown where the registry gives one.
The Institute for Liver Health II LLC DBA Arizona Clinical Trials - Flagstaff
Flagstaff, Arizona
The Institute for Liver Health II LLC DBA Arizona Liver Health - Peoria
Peoria, Arizona
Adobe Clinical Research
Tucson, Arizona
Arizona Liver Health - Tucson
Tucson, Arizona
The Institute for Liver Health II LLC dba Arizona Liver Health
Tucson, Arizona
Del Sol Research Management, LLC
Tucson, Arizona
San Fernando Valley Health Institute
Canoga Park, California
Velocity Clinical Research
Chula Vista, California
Southern California Research Center
Coronado, California
Velocity Clinical Research
Gardena, California
Velocity Clinical Research - Huntington Park
Huntington Park, California
Om Research Llc
Lancaster, California
Ark Clinical Research - Long Beach
Long Beach, California
Ark Clinical Research, LLC
Long Beach, California
Velocity Clinical Research - Westlake
Los Angeles, California
Clinnova Research Solutions
Orange, California
Knowledge Research Center, St. Joseph's Medical Tower
Orange, California
National Research Institute
Panorama City, California
California Liver Research Institute
Pasadena, California
Cadena Care Inst.
Poway, California
Inland Empire Clinical Trials
Rialto, California
Precision Research Institute - San Diego
San Diego, California
University of Colorado Anschutz Medical Campus
Aurora, Colorado
Synergy Healthcare LLC
Bradenton, Florida
Evolution Clinical Trials
Hialeah Gardens, Florida
Health Awareness, inc.
Jupiter, Florida
Miami Clinical Research
Miami, Florida
International Medical Investigational Centers (IMIC) Incorporated
Miami, Florida
Genoma Research Group, Inc.
Miami, Florida
US Associates in Research, LLC
Miami, Florida
Med Research of Florida, LLC
Miami, Florida
Charter Research LLC - Orlando
Orlando, Florida
Indiana University School of Medicine
Indianapolis, Indiana
Deaconess Clinic - GI Specialty Center
Newburgh, Indiana
Tandem Clinical Research
Metairie, Louisiana
Mercy Medical Center
Baltimore, Maryland
GI Associates
Flowood, Mississippi
Washington University School of Medicine
St Louis, Missouri
Columbia University Irving Medical Center
New York, New York
Geisinger Medical Center
Danville, Pennsylvania
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.